GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GRAIL Inc (MEX:GRAL) » Definitions » Cash Flow from Others

GRAIL (MEX:GRAL) Cash Flow from Others : MXN25,058 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is GRAIL Cash Flow from Others?

GRAIL's cash flow from others for the three months ended in Dec. 2024 was MXN-80 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Dec. 2024 was MXN25,058 Mil.


GRAIL Cash Flow from Others Historical Data

The historical data trend for GRAIL's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GRAIL Cash Flow from Others Chart

GRAIL Annual Data
Trend Dec18 Dec19 Dec22 Dec23 Dec24
Cash Flow from Others
-78.44 -48.51 -772.26 -1,257.47 -1,182.48

GRAIL Quarterly Data
Dec18 Dec19 Jun20 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -188.18 -711.32 25,837.76 11.58 -80.09

GRAIL Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN25,058 Mil.

GRAIL Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of GRAIL's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


GRAIL Business Description

Traded in Other Exchanges
Address
1525 O’Brien Drive, Menlo Park, CA, USA, 94025
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.